Gilead Sciences to respond to opposition on hepatitis C drug - (Business Line via NewsPoints Desk)

  • Gilead Sciences said that its Indian patent application for hepatitis C drug sofosbuvir complies with domestic patent laws, Business Line reported.
  • The Initiative for Medicines, Access & Knowledge (I-MAK) had filed a pre-grant opposition against the drug at the Kolkata patent office.
  • Director of I-MAK Tahir Amin remarked "we believe this patent on sofosbuvir does not deserve to be granted in India and have the legal grounds to prove it."
  • “We will respond to the opposition in due course,” Gilead said, adding that it "is currently conducting the necessary clinical trials that are required to register sofosbuvir in India, which we hope will be completed by the end of 2014."

To read more NewsPoints articles, click here.

Reference Articles